CytoSorbents Delays Q4 SEC Filing Amid Currency Adjustments, but Blood‑Purification Tech Remains Strong
CytoSorbents delays Q3 filing to resolve foreign‑currency issues—still poised to scale its blood‑purification tech and drive long‑term growth.
2 minutes to read
